Pilulka Lékárny a.s. (PINK) Fair Value & Analysis
Healthcare · CZ · Market cap 333M CZK
Fair value as of: Jun 24, 2026
From 2 valuation models · updated 5 days ago
Share price −5.5% over the past month.
Price vs Fair Value (12 months)
12‑month range 100.00 CZK – 202.00 CZK · fair‑value band 75.17 CZK – 135.05 CZK · the 121.00 CZK price screens above the 105.11 CZK fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Pilulka Lékárny a.s. (PINK) currently trades at 121.00 CZK, while our model-based Fair Value estimate is 105.11 CZK — implying the stock looks roughly 13.1% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Pilulka Lékárny a.s. generated revenue of 1.3B CZK at a net margin of -9.6%. Net debt stands at 39.7M CZK. Fundamentals as of Jun 24, 2026
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Pilulka Lékárny a.s. operates a network of pharmacy stores under the Pilulka brand in the Czech Republic, Slovakia, Romania, Hungary, and Austria. The company distributes medicinal products; online sale of pharmacy and related goods for health; and healthy lifestyle and services under the Pilulka brand. It also operates Internet portals, such as Pilulka.cz, Pilulka.sk, Pilulka.ro, Pilulka.hu, and Pilulka.at, as well as an e-shop. Pilulka Lékárny a.s. was founded in 2013 and is headquartered in Prague, the Czech Republic.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Pilulka Lékárny a.s. reported revenue of 876M CZK in FY2025 versus 2.4B CZK in FY2021, a compound −22.1%/yr. Reported net income was −38.9M CZK in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc JDHIY | $5.33 | $7.09 | +33% |
| Alibaba Health Information Technology Limited ALBBY | $8.56 | $6.91 | -19% |
| Raia Drogasil S.A RADL3 | R$17.46 | R$16.13 | -8% |
| Yifeng Pharmacy Chain Co 603939 | ¥20.91 | ¥22.00 | +5% |
| Clicks Group CLCGY | $29.02 | $34.57 | +19% |
| Sugi Holdings SGIPF | $16.29 | $64.34 | +295% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Pilulka Lékárny a.s. (PINK) undervalued?
What is the fair value of PINK?
What is the quality score of PINK?
What is the revenue of Pilulka Lékárny a.s. (PINK)?
What is the net profit margin of PINK?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.